GlassScriptPhysician profile
Steven F Lee
NPI 1134118482
$33,067.12
in general payments reported to CMS, 2019-2025
44 companies · $4,822 in 2025
The $4,822 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,399 · 2020: $2,105 · 2021: $3,524 · 2022: $5,557 · 2023: $4,801 · 2024: $4,859 · 2025: $4,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Travel and Lodging: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,315.59 |
| Travel and Lodging | $1,166.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,193.41 | 2019-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $4,540.93 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $3,629.14 | 2022-2025 | Envista Mx60 Iol, Stellaris Elite, Ic-8 Apthera Iol |
| Eyevance Pharmaceuticals LLC | $2,355.14 | 2019-2023 | Flarex |
| Glaukos Corporation | $1,593.90 | 2021-2025 | Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Carl Zeiss Meditec USA, INC. | $1,563.69 | 2022-2025 | Quatera 700, Veracity Surgical, Cirrus Hd-Oct |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,492.70 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $1,328.32 | 2019-2025 | Cequa |
| Abbvie INC. | $1,126.78 | 2022-2025 | |
| Rxsight INC | $1,095.49 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $931.63 | 2019-2022 | |
| Sight Sciences, INC. | $791.76 | 2019-2024 | Omni Surgical System |
| Ivantis, INC | $698.78 | 2019-2021 | |
| Biotissue Holdings INC. | $682.28 | 2019-2024 | |
| Kala Pharmaceuticals, INC. | $623.18 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $586.81 | 2019-2023 | |
| Ocular Therapeutix, INC. | $562.14 | 2019-2025 | Dextenza |
| Harrow Eye, LLC | $524.02 | 2023-2025 | Iheezo, Natacyn, Tobradex St |
| Tarsus Pharmaceuticals, INC. | $462.68 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $388.41 | 2020-2025 | Acthar |
| Dompe US, INC. | $372.53 | 2022-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $300.23 | 2019-2020 | |
| New World Medical,INC. | $269.78 | 2020-2025 | Streamline, Clearpath, Ahmed Glaucoma Valve |
| Oyster Point Pharma, INC. | $268.60 | 2022-2025 | Tyrvaya |
| Horizon Therapeutics Plc | $229.47 | 2019-2023 | Tepezza |
| Beaver-Visitec International, INC. | $198.68 | 2021-2025 | |
| Astellas Pharma US INC | $198.59 | 2023-2025 | Izervay |
| Omeros Corporation | $149.42 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $134.55 | 2022-2023 | |
| Eyepoint US, INC. | $131.27 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $119.66 | 2019-2020 | |
| Shire North American Group INC | $101.64 | 2019 | |
| Genentech USA, INC. | $80.65 | 2022-2025 | Vabysmo |
| Leica Microsystems INC. | $61.00 | 2024 | Surgical Microscopes |
| The Cameron-Ehlen Group, INC. | $48.63 | 2020 | |
| Staar Surgical Company | $47.96 | 2019 | |
| Rayner Intraocular Lenses Limited | $42.15 | 2023 | Rayone Aspheric, Rayone Emv, Omidria |
| Ani Pharmaceuticals, INC. | $41.42 | 2023 | Purified Cortrophin Gel |
| Amgen INC. | $26.12 | 2025 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tearlab Corp | $18.30 | 2019 | |
| Alimera Sciences, INC. | $18.20 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.